OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Bram Verstockt, Azucena Salas, Bruce E. Sands, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 94
Bram Verstockt, Azucena Salas, Bruce E. Sands, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 94
Showing 1-25 of 94 citing articles:
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
Juan Liu, Bin Di, Lili Xu
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 1-12
Closed Access | Times Cited: 68
Juan Liu, Bin Di, Lili Xu
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 1-12
Closed Access | Times Cited: 68
Risankizumab for Ulcerative Colitis
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
JAMA (2024) Vol. 332, Iss. 11, pp. 881-881
Closed Access | Times Cited: 23
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
JAMA (2024) Vol. 332, Iss. 11, pp. 881-881
Closed Access | Times Cited: 23
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
Lisha Li, Jiaye Lu, Jun Liu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 14
Lisha Li, Jiaye Lu, Jun Liu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 14
Host-microbe multi-omics and succinotype profiling have prognostic value for future relapse in patients with inflammatory bowel disease
Janet O’Sullivan, Shriram Patel, Gabriel E. Leventhal, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Janet O’Sullivan, Shriram Patel, Gabriel E. Leventhal, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
IBD Matchmaking - Rational Combination Therapy
Robert Battat, John T. Chang, Edward V. Loftus, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 469-479
Closed Access | Times Cited: 12
Robert Battat, John T. Chang, Edward V. Loftus, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 469-479
Closed Access | Times Cited: 12
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 11
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 11
Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
Arno R. Bourgonje, Ryan C. Ungaro, Saurabh Mehandru, et al.
Gastroenterology (2024)
Closed Access | Times Cited: 10
Arno R. Bourgonje, Ryan C. Ungaro, Saurabh Mehandru, et al.
Gastroenterology (2024)
Closed Access | Times Cited: 10
The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 9
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 9
Network pharmacology mechanisms and experimental verification of licorice in the treatment of ulcerative colitis
Jinrong Kong, Qingzhen Xiang, Wanyue Ge, et al.
Journal of Ethnopharmacology (2024), pp. 117691-117691
Closed Access | Times Cited: 8
Jinrong Kong, Qingzhen Xiang, Wanyue Ge, et al.
Journal of Ethnopharmacology (2024), pp. 117691-117691
Closed Access | Times Cited: 8
Sequential immunotherapy: towards cures for autoimmunity
Francisco Ramírez‐Valle, Joseph Maranville, Sophie Roy, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 7, pp. 501-524
Closed Access | Times Cited: 8
Francisco Ramírez‐Valle, Joseph Maranville, Sophie Roy, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 7, pp. 501-524
Closed Access | Times Cited: 8
Traditional Chinese medicine treats ulcerative colitis by regulating gut microbiota, signaling pathway and cytokine: Future novel method option for pharmacotherapy
Tiancheng Wang, Xinyue Liu, Weijie Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27530-e27530
Open Access | Times Cited: 7
Tiancheng Wang, Xinyue Liu, Weijie Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27530-e27530
Open Access | Times Cited: 7
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Mirikizumab (Omvoh™) for ulcerative colitis
Alexander Hammerhøj, Theresa Louise Boye, Ebbe Langholz, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 3, pp. 281-282
Open Access | Times Cited: 6
Alexander Hammerhøj, Theresa Louise Boye, Ebbe Langholz, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 3, pp. 281-282
Open Access | Times Cited: 6
Autophagy: A potential target for natural products in the treatment of ulcerative colitis
Wei Zhang, Menglong Zou, Jia Fu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116891-116891
Open Access | Times Cited: 6
Wei Zhang, Menglong Zou, Jia Fu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116891-116891
Open Access | Times Cited: 6
Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease
Zhezhe Tian, Qiaorui Zhao, Xiu Teng
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Zhezhe Tian, Qiaorui Zhao, Xiu Teng
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus
Masayuki Mizui, Michihito Kono
Clinical Immunology (2024) Vol. 262, pp. 110182-110182
Closed Access | Times Cited: 5
Masayuki Mizui, Michihito Kono
Clinical Immunology (2024) Vol. 262, pp. 110182-110182
Closed Access | Times Cited: 5
Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review
Hiroki Kurumi, Yoshihiro Yokoyama, Takehiro Hirano, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 952-952
Open Access | Times Cited: 5
Hiroki Kurumi, Yoshihiro Yokoyama, Takehiro Hirano, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 952-952
Open Access | Times Cited: 5
The multiple roles of interferon regulatory factor family in health and disease
Lianzhou Wang, Yanghui Zhu, Nan Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Lianzhou Wang, Yanghui Zhu, Nan Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Discovery of 7-Azaindole Inhibitors of Inflammasomes/Il-1β for the Treatment of Inflammatory Bowel Disease
Yuyun Yan, Xiuxiu Zhang, Ruiwen Wu, et al.
(2025)
Closed Access
Yuyun Yan, Xiuxiu Zhang, Ruiwen Wu, et al.
(2025)
Closed Access
Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances
Michael Colwill, Jennifer Clough, Samantha Baillie, et al.
Frontline Gastroenterology (2025), pp. flgastro-102830
Closed Access
Michael Colwill, Jennifer Clough, Samantha Baillie, et al.
Frontline Gastroenterology (2025), pp. flgastro-102830
Closed Access
Inflammation-Induced Th17 Cells Synergize with the Inflammation-Trained Microbiota to Mediate Host Resiliency Against Intestinal Injury
Jonathan L. Golob, Guoqing Hou, Benjamin Swanson, et al.
Inflammatory Bowel Diseases (2025)
Open Access
Jonathan L. Golob, Guoqing Hou, Benjamin Swanson, et al.
Inflammatory Bowel Diseases (2025)
Open Access
Systematic Review of Interleukin‐35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention
Kai Li, Jie Feng, Meng Li, et al.
Mediators of Inflammation (2025) Vol. 2025, Iss. 1
Open Access
Kai Li, Jie Feng, Meng Li, et al.
Mediators of Inflammation (2025) Vol. 2025, Iss. 1
Open Access
Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-α antibody therapeutic in ulcerative colitis treatment
Yicheng Zhang, Ling Li, Jiayuan Kong, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 1005-1016
Closed Access
Yicheng Zhang, Ling Li, Jiayuan Kong, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 1005-1016
Closed Access
Risk factors for humanized IgG1 monoclonal antibody in the treatment of Crohn's disease: pharmacovigilance of the FDA adverse event reporting system (FAERS)
Jiangchuan Xie, Chun Tao, Linli Xie, et al.
Research Square (Research Square) (2025)
Closed Access
Jiangchuan Xie, Chun Tao, Linli Xie, et al.
Research Square (Research Square) (2025)
Closed Access
